Reports Q2 revenue $77.22B, consensus $75.83M. “McKesson delivered second quarter results above expectations, demonstrating continued progress against our company priorities,” said Brian Tyler, chief executive officer. “This performance and continued momentum reflect the dedication and contribution of our McKesson team members. The continued strength of our differentiated capabilities in our oncology and biopharma services platforms positions McKesson to deliver sustainable growth and compelling long-term shareholder value.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MCK:
- Notable companies reporting after market close
- Is MCK a Buy, Before Earnings?
- Citi ups McKesson target, opens ‘positive catalyst watch’
- McKesson stock looking like a Buy, Barron’s says
- McKesson price target raised to $490 from $485 at Evercore ISI
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue